WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

I am an American from South Florida and after completing my Asian Studies undergraduate degree from Florida International University, I moved to Wuxi and became an English teacher. I've been doing ...

SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ...

With potential passage of the BIOSECURE Act looming and WuXi Biologics seeing its share price and profits decline, the Chinese biopharma contract manufacturing giant is responding with a sizable ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released lower-than ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...

Pharma giant MSD is buying the Dundalk-based vaccines plant of Chinese rival Wuxi in a €500 million deal. Wuxi invested €200 million in 2019 to build the plant, which currently employs 200 ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a $925 million biobucks deal with WuXi Biologics for a preclinical candidate.

Moore caught 32 of his 57 targets for 351 yards and three touchdowns across 17 regular-season games in 2024. Moore had one of the most productive seasons of his career with Carolina in 2024 ...